Every year on November 20th, World Children’s Day reminds us of the importance of promoting children's rights and improving their welfare globally. Established by the United Nations in 1954, this day highlights the need for every child to have access to quality healthcare, education, and protection from harm. In this article we look at some of the ways ICON advances pediatric healthcare by supporting pediatric clinical trials.
The significance of World Children’s Day
World Children’s Day commemorates the adoption of the UN Convention on the Rights of the Child in 1989, the most widely ratified human rights treaty in history. This treaty has motivated governments to make important changes, ensuring more children receive the healthcare, nutrition, and protection they need to grow and thrive. Yet, there is still much work to be done to ensure that every child, no matter where they are born or their circumstances, has the healthcare access they deserve. At ICON, we joined the world in recognising this day, reflecting on the vital role of pediatric healthcare in shaping a healthier future for the youngest members of our global community.
Making pediatric clinical trials more inclusive
Historically, pediatric populations have often been excluded from clinical research, leaving a gap in treatments that are proven to be safe, effective, and specifically designed for children. Our Centre for Pediatric Clinical Development is committed to improving healthcare access and inclusivity for children around the world. A critical part of this mission is ensuring that children have the opportunity to participate in clinical trials from the outset. By prioritising pediatric inclusion in clinical trials, we can ensure that therapies are developed with the unique needs of children in mind, leading to more approved treatments specific to children and better health outcomes.
Education and communication
Families and caregivers play a crucial role in supporting children’s health and in granting permission for their inclusion in clinical trials. Many families are unaware of how clinical trials contribute to the development of better treatments for children or may have concerns about participating. By providing clear, accessible information and support, we aim to empower parents and caregivers to make informed decisions about their child’s participation. Education is key to improving trust, participation, and ultimately, expanding the number of pediatric treatments available. Age-appropriate information for children is also provided so that children understand their role and rights when participating in clinical trials. This can be done in fun and interactive ways, with activity books and even board games that explain the clinical trial process. ICON's Language Services team can translate this information into culturally appropriate content and languages for target populations globally, and even different language groups within the same regions.
Using technology to improve access to healthcare
Advances in technology have expanded the possibilities in healthcare and can be used to overcome barriers to healthcare access. Digital health solutions, telehealth appointments and at-home patient services can ensure that children in even the most underserved areas benefit from clinical trial participation. Technology can remove some of the burdens of clinical trial participation making the process more attractive to families already coping with their child’s health challenges. By leveraging technology, we can improve diagnostics, expand healthcare reach, and ensure timely access to life-saving treatments.
Conclusion
Progress has been made but there is still more to do. Today 50% of approved drugs are labeled for pediatric use, compared to just 20% thirty years ago. ICON remains focused on enhancing access to safe, accurately dosed pediatric medications and fostering global collaboration to continue this vital work. As we reflect on World Children’s Day, we reaffirm our commitment to ensure that all children, everywhere, have the healthcare they need to lead healthy, productive lives. Together, we can build a future where every child thrives.
Contact us to find out how we can support your pediatric clinical trials.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel